UGT1A7 Antibody (B-12): sc-377075

UGT1A7 Antibody (B-12) is a mouse monoclonal IgG3 kappa light chain antibody that detects UGT1A7 protein of mouse and rat origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-UGT1A7 antibody (B-12) is available as the non-conjugated form. UGT1A7 is a member of the UDP-glucuronosyltransferase superfamily, which plays a crucial role in the detoxification of bile acids through glucuronidation. This enzymatic activity is vital for the metabolism of various drugs and xenobiotics, as glucuronidation facilitates excretion from the body. UGT1A7 is primarily localized in the liver, where UGT1A7 contributes to drug metabolism regulation and clearance of potentially harmful substances. The liver′s unique architecture and blood supply allow for efficient processing of these compounds, making UGT1A7 essential for maintaining metabolic homeostasis. Expression of UGT1A7 can be influenced by various nuclear receptors, which may lead to variations in activity based on physiological conditions or exposure to different substances. Understanding UGT1A7 function and regulation is important for elucidating drug interactions and potential implications for therapeutic efficacy and safety.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

UGT1A7 Antibody (B-12) References:

1. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk.  |  Zheng, Z., et al. 2001. J Natl Cancer Inst. 93: 1411-8. PMID: 11562393
2. Chromosomal assignment of human phenol and bilirubin UDP-glucuronosyltransferase genes (UGT1A-subfamily).  |  Moghrabi, N., et al. 1992. Ann Hum Genet. 56: 81-91. PMID: 1503396
3. Comparative genomics analysis of human sequence variation in the UGT1A gene cluster.  |  Maitland, ML., et al. 2006. Pharmacogenomics J. 6: 52-62. PMID: 16314881
4. Monospecific antipeptide antibodies against human hepatic UDP-glucuronosyltransferase 1A subfamily (UGT1A) isoforms.  |  Ikushiro, S., et al. 2006. Drug Metab Pharmacokinet. 21: 70-4. PMID: 16547396
5. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.  |  Han, JY., et al. 2006. J Clin Oncol. 24: 2237-44. PMID: 16636344
6. Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus.  |  Thomas, SS., et al. 2006. Hum Mutat. 27: 717. PMID: 16786511
7. Shared regulation of UGT1A7 by hepatocyte nuclear factor (HNF) 1alpha and HNF4alpha.  |  Ehmer, U., et al. 2010. Drug Metab Dispos. 38: 1246-57. PMID: 20406851
8. UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.  |  Wang, C., et al. 2024. Cancer Gene Ther. 31: 1525-1535. PMID: 39122832
9. Genetic defects at the UGT1 locus associated with Crigler-Najjar type I disease, including a prenatal diagnosis.  |  Ciotti, M., et al. 1997. Am J Med Genet. 68: 173-8. PMID: 9028453
10. The novel UGT1 gene complex links bilirubin, xenobiotics, and therapeutic drug metabolism by encoding UDP-glucuronosyltransferase isozymes with a common carboxyl terminus.  |  Owens, IS., et al. 1996. J Pharmacokinet Biopharm. 24: 491-508. PMID: 9131487
11. Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer.  |  Strassburg, CP., et al. 1997. Cancer Res. 57: 2979-85. PMID: 9230212
12. Characterization of rabbit UDP-glucuronosyltransferase UGT1A7: tertiary amine glucuronidation is catalyzed by UGT1A7 and UGT1A4.  |  Bruck, M., et al. 1997. Arch Biochem Biophys. 348: 357-64. PMID: 9463278

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-UGT1A7 Antibody (B-12) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-UGT1A7 Antibody (B-12) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

UGT1A7 Antibody (B-12) Specifications

Alternate Product Name: UGT1A7

Product Clone Name: B-12

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₃ kappa light chain

Amino Acids: 93-127

Epitope Target: UGT1A7

Epitope Species: rat

Product Reactivity/Detection: UGT1A7

Species Reactivity/Detection: mouse, rat

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₃ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for UGT1A7 Antibody (B-12): P: Blocking Peptide

The preferred UGT1A antibody is UGT1A Antibody (B-4): sc-271268.